Meiser Peter

Dr. Meiser Peter

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

12 December 2006 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
MPMeiser Peter
Meiser Peter
HBHelge B. Bode
Helge B. Bode
RMRolf Müller
Rolf Müller
Under starvation conditions myxobacteria form multicellular fruiting bodies in which vegetative cells differentiate into heat- and desiccation-resistant myxospores. Myxobacteria in general are a rich source of secondary metabolites that often exhibit biological activities rarely found in nature. Although the involvement of a yellow compound in sporulation and fruiting body formation of Myxococcus xanthus was described almost 30 years ago, the chemical principle of the pigment remained elusive. This work presents the isolation and structure elucidation of a unique class of pigments that were named DKxanthenes (DKX). The corresponding biosynthetic gene cluster was identified, and DKX-negative mutants were constructed to investigate the physiological role of DKX during development. In these mutants, fruiting body formation was delayed. Moreover, severely reduced amounts of viable spores were observed after 120 h of starvation, whereas no viable spores were formed at all after 72 h. The addition of purified DKX to the mutants resulted in the formation of viable spores after 72 h. Even though an antioxidative activity could be assigned to DKX, the true biochemical mechanism underlying the complementation remains to be elucidated.

17 March 2006 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
SWSilke C. Wenzel
Silke C. Wenzel
MPMeiser Peter
Meiser Peter
TBTina M. Binz
Tina M. Binz
TMTaifo Mahmud
Taifo Mahmud
RMRolf Müller
Rolf Müller

1 August 2008 in Chemistry & Biology
Verified
Journal Article
Closed access
MPMeiser Peter
Meiser Peter
KWKira J. Weissman
Kira J. Weissman
HBHelge B. Bode
Helge B. Bode
Daniel KrugDaniel Krug
Daniel Krug
JDJeroen S. Dickschat
Jeroen S. Dickschat
RMRolf Müller
Rolf Müller

20 April 2012 in Phytotherapy Research
Verified
Journal Article
Closed access
PDF file
SMSilke Müller
Silke Müller
RMReinhard März
Reinhard März
MSManfred Schmolz
Manfred Schmolz
BDBernd Drewelow
Bernd Drewelow
KEKlaus Eschmann
Klaus Eschmann
MPMeiser Peter
Meiser Peter

1 March 2011 in Molecular BioSystems
Verified
Journal Article
Closed access
PDF file
MKMaren Kopp
Maren Kopp
HIHerbert Irschik
Herbert Irschik
KGKatja Gemperlein
Katja Gemperlein
KBKathrin Buntin
Kathrin Buntin
MPMeiser Peter
Meiser Peter
RMRolf Müller
Rolf Müller
The anti-fungal leupyrrins are secondary metabolites produced by several strains of the myxobacterium Sorangium cellulosum. These intriguing compounds incorporate an atypically substituted γ-butyrolactone ring, as well as pyrrole and oxazolinone functionalities, which are located within an unusual asymmetrical macrodiolide. Previous feeding studies revealed that this novel structure arises from the homologation of four distinct structural units, nonribosomally-derived peptide, polyketide, isoprenoid and a dicarboxylic acid, coupled with modification of the various building blocks. Here we have attempted to reconcile the biosynthetic pathway proposed on the basis of the feeding studies with the underlying enzymatic machinery in the S. cellulosum strain So ce690. Gene products can be assigned to many of the suggested steps, but inspection of the gene set provokes the reconsideration of several key transformations. We support our analysis by the reconstitution in vitro of the biosynthesis of the pyrrole carboxylic starter unit along with gene inactivation. In addition, this study reveals that a significant proportion of the genes for leupyrrin biosynthesis are located outside the core cluster, a ‘split’ organization which is increasingly characteristic of the myxobacteria. Finally, we report the generation of four novel deshydroxy leupyrrin analogues by genetic engineering of the pathway.